FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Cormack Scott Daniel
   2. Issuer Name and Ticker or Trading Symbol
ONCOGENEX PHARMACEUTICALS, INC. [OGXI] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
President and CEO
(Last)
(First)
(Middle)
400-1001 W. BROADWAY		 3. Date of Earliest Transaction (Month/Day/Year)
08/21/2008
(Street)

VANCOUVER, A1 V6H 4B1		 4. If Amendment, Date Original Filed(Month/Day/Year)
08/21/2008		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
stock option (right to buy) $ 3.889 (1) 08/21/2008   A   24,825 (2)   08/21/2008 01/01/2009 Common Stock 24,825 (3) 24,825 D  
Stock option (right to buy) $ 3.889 (1) 08/21/2008   A   871 (4)   08/21/2008 08/01/2009 Common stock 871 (5) 871 I By Spouse
Stock option (right to buy) $ 3.889 (1) 08/21/2008   A   7,077 (6)   08/21/2008 02/01/2010 Common Stock 7,077 (7) 7,077 I By Spouse
Stock option (right to buy) $ 3.889 (1) 08/21/2008   A   20,470 (8)   08/21/2008 12/16/2010 Common Stock 20,470 (9) 20,470 D  
Stock option (right to buy) $ 3.889 (1) 08/21/2008   A   6,533 (10)   08/21/2008 12/16/2010 Common stock 6,533 (11) 6,533 I By Spouse
Stock option (right to buy) $ 3.889 (1) 08/21/2008   A   21,559 (12)   08/21/2008 01/14/2011 Common Stock 21,559 (13) 21,559 D  
Stock option (right to buy) $ 3.889 (1) 08/21/2008   A   6,859 (6)   08/21/2008 01/14/2011 Common Stock 6,859 (14) 6,859 I By Spouse
Stock option (right to buy) $ 4.1051 (15) 08/21/2008   A   46,167 (16)   08/21/2008 08/08/2012 Common Stock 46,167 (17) 46,167 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Cormack Scott Daniel
400-1001 W. BROADWAY
VANCOUVER, A1 V6H 4B1		   X     President and CEO  

Signatures

 Sandra Thomson as Attorney-in-fact for Scott Cormack   02/02/2009
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Due to an administrative error, the original Form 4 overstated the exercise price by $0.0025.
(2) Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 16.
(3) Received in exchange for a stock option to acquire 114,000 shares of OncoGenex Technologies Inc. ("OncoGenex Technologies") common stock for CAD$0.90 per share in connection with an arrangement between OncoGenex Technologies and OncoGenex Pharmaceuticals, Inc. (the "Arrangement").
(4) Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 1.
(5) Received in the Arrangement in exchange for a stock option to acquire 4,000 shares of OncoGenex Technologies common stock for CAD$0.90 per share.
(6) Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 4.
(7) Received in the Arrangement in exchange for a stock option to acquire 32,500 shares of OncoGenex Technologies common stock for CAD$0.90 per share.
(8) Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 13.
(9) Received in the Arrangement in exchange for a stock option to acquire 94,000 shares of OncoGenex Technologies common stock for CAD$0.90 per share.
(10) Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 5.
(11) Received in the Arrangement in exchange for a stock option to acquire 30,000 shares of OncoGenex Technologies common stock for CAD$0.90 per share.
(12) Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 14.
(13) Received in the Arrangement in exchange for a stock option to acquire 99,000 shares of OncoGenex Technologies common stock for CAD$0.90 per share.
(14) Received in the Arrangement in exchange for a stock option to acquire 31,500 shares of OncoGenex Technologies common stock for CAD$0.90 per share.
(15) Due to an administrative error, the original Form 4 overstated the exercise price by $0.0026.
(16) Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 30.
(17) Received in the Arrangement in exchange for a stock option to acquire 212,000 shares of OncoGenex Technologies common stock for CAD$0.95 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.